

** 2015 ASAM Guidelines for the Use of Medications in Opioid Addictions: What Providers Need to Know about Implementing It into Practice*

Jessica L. Estes, DNP, APRN-NP
APNA 2016 Annual Conference

*This provider has no conflicts of interest to disclose.

***Disclosures**

- *To review the ASAM guidelines on the treatment of opioid addiction
- *To develop an understanding of where medication assisted treatment can help
- *To implement the guidelines into practice in primary care and psychiatric settings

***Objectives**

- *A clinical tool used to help prescribers determine the appropriate medication treatment protocols for opioid addictions
- *It's the FIRST prescriber reference to include all medications used in the treatment of opioid addictions.

***What are the 2015 ASAM Guidelines**

- *2014 recorded the highest number of overdose deaths on record
- *6/10 of those deaths had opiates involved
- *78 Americans die daily from opiates
- *Since the late 1990s the number of opiate prescriptions had quadrupled

***Why are they important?**

- * Assessment of Addiction and Potential for abuse
- * Diagnosis of a substance use disorder meeting the DSM V criteria
- * Plan for Intervention with the patient and family
- * Interventions psychosocially and medication assisted treatment
- * Evaluate the effectiveness of treatment at regular intervals

***Nursing Process Implications**

- *Clinical Screening Tool
- *Physical Assessment to rule out acute issue
- *UDT
 - *Point of Care vs. Confirmation
 - * 6, 10, or 13, panel vs. custom panels
- *Psychosocial assessment
- *<http://asamcontinuum.org/>

*Assessment Should Include

- *WHO-DAS
 - *Good global assessment of well-being
 - *International standard
- *AUDIT
 - *Focuses on Alcohol - but needed for concurrent addictions
- *DAST
 - *Focuses primarily on drug abuse
- *CAGE
 - *Common primary screening tool that can signal a need to look at other scales

*Clinical Assessment Tools

- *No longer substance abuse or addiction
- *Correct terms are
 - *Opioid Use Disorder
 - *Opioid Intoxication
 - *Opioid Withdrawal

*Diagnosis Chances with the DSM V

*At Least 2 of the following:
*They are used in larger amounts and a longer period than intended
*There's a desire or persistent effort to cut down
*Cravings for the substance
*Recurrent use = role fulfillment failures
*Continued use despite deterrents
*Use that results in hazardous situations
*Use despite knowledge of reliance or dependence
*Withdrawal

***Opioid Use Disorder
DSM V Criteria**

*They are in remission
*Early or Sustained
*Maintenance or controlled environment
*Severity
*Mild 2-3 symptoms
*Moderate 4-5 symptoms
*Severe 6+

***Specify if:**

*Intoxication
*Recent use
*Clinically significant symptoms
*Withdrawal
*Presence of (decrease or complete end of long-term use) or
*Medication assisted antagonist
*Three or more: changed mood, NVD, nasal complaints, yawning, fever, insomnia

***Intoxication or
Withdrawal as a DX**

*Determine treatment options:
*Inpatient
*Partial Hospitalization
*Intensive Outpatient
*Outpatient
*Medication assisted therapies

***Plan**

*Clonidine
*Buprenorphine
*Buprenorphine and Naltrexone

***Intervention:
Treating Withdrawal**

*Naltrexone
*Oral Versus Injectable
*Buprenorphine
*Methadone

***Intervention:
Medication Assisted
Treatment**

- *Narcotics Anonymous
- *Individual Therapy
 - *CBT, Trauma focused care
- *Group Therapy
- *Legal Assistance

***Intervention:
Psychosocial Supports**

- *Pregnancy
- *Age
- *Mental Health Co-morbidities
- *Availability of Treatment options
 - *Detox, then partial, then intensive outpatient, then outpatient, plus long-term medications or short term
- *Medicaid vs Private Insurances

***Intervention:
Confounding Factors**

- *RANDOM
 - *UDT or saliva
 - *Making sure panel includes natural and synthetic opiates
 - *Medication Counts
- *Collateral from family
- *Interdisciplinary Collaboration with mental health, pain management, etc.

***Evaluation**

*Section 303 of the Comprehensive Addiction and Recovery Act (CARA), signed into law by President Obama on July 22, 2016, made several changes to the law regarding office-based opioid addiction treatment with buprenorphine.

*One of these changes is that prescribing privileges have been expanded to nurse practitioners (NPs) and physician assistants (PAs) for five years (until October 1, 2021). At the moment, there is no set date when NPs and PAs will be able to apply to receive a waiver to prescribe buprenorphine. A separate application form will need to be approved by the federal government for NPs and PAs to apply for a waiver to prescribe buprenorphine.

*Any NP or PA who begins to prescribe buprenorphine before applying for and receiving a waiver will be in violation of federal law.

*For NPs and PAs to be eligible to apply for a buprenorphine waiver, they must complete 24 hours of training that covers the following topics: opioid maintenance and detoxification; clinical use of all FDA-approved drugs for medication-assisted treatment; patient assessment; treatment planning; psychosocial services; staff roles; and diversion control.

***2016 CARA FYI**

American Psychiatric Nurses Association. (2014). *Psychiatric Mental Health Nursing: Scope and Standards of Practice* (2nd ed.). Silver Spring, MD: American Nurses Association.

Centers for Disease Control and Prevention. Increases in Drug and Opioid Overdose Deaths — United States, 2000-2014. *MMWR* 2015; 64:1-5.

CDC. Wide-ranging online data for epidemiologic research (WONDER). Atlanta, GA: CDC, National Center for Health Statistics; 2016. Available at <http://wonder.cdc.gov>.

Chang H, Daubresse M, Kruszewski S, et al. Prevalence and treatment of pain in emergency departments in the United States, 2000 - 2010. *Amer J of Emergency Med* 2014; 32(5): 421-31.

Daubresse M, Chang H, Yu Y, Viswanathan S, et al. Ambulatory diagnosis and treatment of nonmalignant pain in the United States, 2000 - 2010. *Medical Care* 2013; 51(10): 870-878.

***References and Links**

Morrison, J. (2014). *DSM-5 Made Easy: The Clinician's Guide to Diagnosis*. New York, NY: The Guilford Press.

Morrison, J. (2015). *Diagnosis Made Easier: Principles and Techniques for Mental Health Clinicians* (2nd ed.). New York, NY: The Guilford Press

Sadock, B. S. (2014). *Kaplan & Sadock's Pocket Handbook of Psychiatric Drug Treatment* (6th ed.). Philadelphia, PA: Wolters Kluwer.

<http://www.asam.org/docs/default-source/practice-support/quality-improvement/>

<http://www.asam.org/quality-practice/guidelines-and-consensus-documents/npg>

<https://www.guidelinecentral.com/shop/use-of-medications-in-the-treatment-of-addiction-involving-opioid-use-guidelines-pocket-card/>

***Links**
